微信直播

ITMIG 2017 | Ugo Pastorino:对于早期胸腺瘤患者,选择开胸手术还是微创手术?

Published at: 2015年第1卷第S1期

黄诗婷
关键词:

编者按:由国际胸腺肿瘤协会(International Thymic Malignancy Interesting Group, ITMIG)举办的第8届年会于2017年9月21日-23日在意大利都灵Lingotto会议中心圆满召开。来自意大利Fondazione IRCCS Istituto Nazionale Tumori胸外科的Ugo Pastorino教授就“Extended Surgical Resection for Stage III Thymic Tumors”一题作了精彩的演讲。会后,我们十分荣幸地采访到了Pastorino教授。

图1. Ugo Pastorino教授发表精彩演讲

专家简介:Ugo Pastorino

Ugo Pastorino, MD

Ugo Pastorino graduated in Medicine in 1979 at the University of Milan and specialized in Emergency Surgery, Oncology and Thoracic Surgery. In 1991 launched the International Registry of Lung Metastases. Appointed as consultant thoracic surgeon at the Royal Brompton Hospital of London in 1994, is Director of Thoracic Surgery at the Istituto Nazionale Tumori of Milan from 2003, and Scientific Director in 2014/2015. From 2001 to 2014 was Associate Editor of the Journal of the National Cancer Institute, and from 2014 is Editor in Chief of Tumori Journal. Author of 332 papers with Impact Factor (H-index: 48), has been principal investigator of a number of randomised trials on chemoprevention and adjuvant chemotherapy, and is presently responsible of three prospective trials on lung cancer screening with LDCT and circulating biomarkers.

在访谈中,Pastorino教授向我们介绍了在胸腺瘤手术中,开胸手术是最为常见的手术方式。对于III期胸腺肿瘤在扩大切除手术前,医生们往往是需要考虑进行新辅助治疗的。作为一名肺外科专家,Pastorino教授致力于研究多原发肺小结节治疗已有二十余年,他与我们分享了他们团队在对非实性病变或部分实性的病变实施将近10年的主动监测的研究成果。他提出,大部分的该类型病变不会进一步发展,但有时候实性病变部分会增长,因此医生要控制好病变的情况。而随着CT检查的进步,出现过度治疗的情况也减少了。在采访的最后,Pastorino教授针对肺癌患者在液体活检技术在术前及术后的评估也提出自己宝贵的看法。

图2. 合影留念

欲知更多精彩内容,欢迎点击下方视频。

采访问题

1. The surgical outcome of patients with early stage thymoma is generally pleasant. In you center, which approach do you apply more for those patients? Minimally invasive surgery or open surgery?

2. Prior to extended resection surgery for patients with stage Ⅲ thymoma, is it necessary to consider neoadjuvant therapy?

3. You have contributed significantly to field of pulmonary surgery. From your experiences, how to choose strategies for the treatment of multiple primary GGO/GGN? (ground-glass opacity/ ground-glass nodules)

4. Screening of lung cancer has generally lowered its mortality. In your center, what’s the proportion of postoperative benign pathologic results in patients with suspicion of early stage NSCLC patients? How to control and reduce potential excessive treatment?

5. How do you see the estimation of liquid biopsy in pre-operation and post-operation for lung cancer patients?

相关阅读:

采写编辑:黄诗婷 AME Publishing Company

特别鸣谢:成都大学附属医院胸心外科冷雪峰医生为本次采访提供策划和指导。

comments powered by Disqus

附件